ENDRA Life Sciences (NDRA) Shares Outstanding (Weighted Average) (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $1.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $1.2 million, up 115.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 115.14% YoY), and the FY2025 annual result was $787020.0, up 335.52% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $1.2 million in Q1 2026 per NDRA's latest filing, from $787020.0 in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $6.4 million in Q4 2023 and troughed at $4391.0 in Q3 2023.
• A 5-year average of $1.7 million and a median of $787020.0 in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) plunged 99.86% in 2023, then jumped 8931.13% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.9 million in 2022, then surged by 120.1% to $6.4 million in 2023, then slumped by 96.82% to $202106.0 in 2024, then surged by 289.41% to $787020.0 in 2025, then surged by 52.42% to $1.2 million in 2026.
• Business Quant data shows NDRA's Shares Outstanding (Weighted Average) at $1.2 million in Q1 2026, $787020.0 in Q4 2025, and $180707.0 in Q3 2025.